Evidence map›Paper›PMID 37144019›Full record

ArticleAnnals of gastroenterology

Comparing adalimumab and infliximab in the prevention of postoperative recurrence of Crohn's disease: a systematic review and meta-analysis.

Manesh Kumar Gangwani, Mohamad Nawras, Muhammad Aziz, Anooja Rani, Fnu Priyanka, Dushyant Singh Dahiya, Zohaib Ahmed, Amir Humza Sohail, Rahul Karna, Wade Lee-Smith and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Manesh Kumar GangwaniDepartment of Medicine, University of Toledo Medical Center, Toledo, Ohio, USA (Manesh Kumar Gangwani, Mohamad Nawras, Zohaib Ahmed).
Mohamad NawrasDepartment of Medicine, University of Toledo Medical Center, Toledo, Ohio, USA (Manesh Kumar Gangwani, Mohamad Nawras, Zohaib Ahmed).
Muhammad AzizDivision of Gastroenterology and Hepatology, University of Toledo Medical Center, Toledo, Ohio, USA (Muhammad Aziz, Abdallah Kobeissy, Yaseen Alastal).
Anooja RaniDepartment of Medicine, Dow University of Health Sciences, Karachi, Pakistan (Anooja Rani).
Fnu PriyankaDivision of Medicine, Shaheed Mohtarma Benazir Bhutto University, Larkana, Pakistan (Fnu Priyanka).
Dushyant Singh DahiyaDepartment of Medicine, Central Michigan University College of Medicine, Saginaw, MI, USA (Dushyant Singh Dahiya).
Zohaib AhmedDepartment of Medicine, University of Toledo Medical Center, Toledo, Ohio, USA (Manesh Kumar Gangwani, Mohamad Nawras, Zohaib Ahmed).
Amir Humza SohailDepartment of General Surgery, New York University Langone Health, Long Island, NY, USA (Amir Humza Sohail).
Rahul KarnaDepartment of Medicine, Alleghany General Hospital, PA, USA (Rahul Karna).
Wade Lee-SmithUniversity of Toledo Libraries, University of Toledo, Toledo, Ohio, USA (Wade Lee-Smith).
Faisal KamalDivision of Gastroenterology, University of San Francisco, San Francisco, USA (Faisal Kamal).
Abdallah KobeissyDivision of Gastroenterology and Hepatology, University of Toledo Medical Center, Toledo, Ohio, USA (Muhammad Aziz, Abdallah Kobeissy, Yaseen Alastal).
Yaseen AlastalDivision of Gastroenterology and Hepatology, University of Toledo Medical Center, Toledo, Ohio, USA (Muhammad Aziz, Abdallah Kobeissy, Yaseen Alastal).
University of Toledo Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Crohn's disease is a relapsing disease that often requires operative management. Prevention of postoperative recurrence (POR) is critical to maintain remissions. Biologic agents have proven to be most successful in remission maintenance. We made a direct head-to-head comparison of the 2 anti-tumor necrosis factor agents, infliximab (IFX) and adalimumab (ADA), to compare endoscopic and clinical POR of Crohn's disease. Methods: We conducted a comprehensive literature search in 7 databases, including Medline, Embase, Cochrane Central Register of Controlled Trials, Web of Science Core Collection, KCI-Korean Journal Index, SciELO, and Global Index Medicus. Odds ratios (OR) were calculated with 95% confidence intervals (CI) and P-values (<0.05 considered significant). We evaluated the total rates of endoscopic recurrence, endoscopic recurrence at 1 year, and clinical recurrence rates of IFX and ADA in a direct head-to-head comparison. Results: The search strategy yielded a total of 393 articles. Three studies with a total of 268 participants were included. Our meta-analysis showed no statistically significant difference in total endoscopic recurrence rate between ADA and IFX (27.1% vs. 32.3%, OR 0.696, 95%CI 0.403-1.201; P=0.193; Conclusions: ADA and IFX show comparable efficacy in preventing POR endoscopically and clinically. The clinical decision should be based on cost, side-effects, tolerability, and patient preferences. Additional studies, particularly randomized controlled trials, are needed to determine generalizability.

Indexed as

adalimumabbiologicsCrohn’s diseaseinfliximabPostoperative recurrence

Identifiers

PMID37144019
PMCPMC10152807
OpenAlexW4372333970

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.